|Synonyms||DiGeorge anomaly, velocardiofacial syndrome (VCFS), Shprintzen syndrome, conotruncal anomaly face syndrome (CTAF), Takao syndrome, Sedlackova syndrome, Cayler cardiofacial syndrome, Strong syndrome, congenital thymic aplasia, thymic hypoplasia, 22q11.2 deletion syndrome|
|A child with DiGeorge syndrome|
|Symptoms||Variable; commonly congenital heart problems, specific facial features, cleft palate|
|Complications||Kidney problems, hearing loss, autoimmune disorders|
|Causes||Genetic (typically new mutation)|
|Prognosis||Depends on the specific symptoms|
|Frequency||1 in 4,000|
DiGeorge syndrome, also known as 22q11.2 deletion syndrome, is a syndrome caused by the deletion of a small segment of chromosome 22. While the symptoms can be variable they often include congenital heart problems, specific facial features, frequent infections, developmental delay, learning problems, and cleft palate. Associated condition include kidney problems, hearing loss, and autoimmune disorders such as rheumatoid arthritis and Graves disease.
DiGeorge syndrome is due to the deletion 30 to 40 genes in the middle of chromosome 22 at a location known as 22q11.2. About 90% of cases occurs due to a new mutation during early development while 10% are inherited from a person's parents. It is autosomal dominant. Treatment may benefit from a multidisciplinary approach with efforts to improve the function of many organ systems.
Signs and symptoms
The features of this syndrome vary widely, even among members of the same family, and affect many parts of the body. Characteristic signs and symptoms may include birth defects such as congenital heart disease, defects in the palate, most commonly related to neuromuscular problems with closure (velopharyngeal insufficiency), learning disabilities, mild differences in facial features, and recurrent infections. Infections are common in children due to problems with the immune system's T-cell-mediated response that in some patients is due to an absent or hypoplastic thymus. DiGeorge syndrome may be first spotted when an affected newborn has heart defects or convulsions from hypocalcemia due to malfunctioning parathyroid glands and low levels of parathyroid hormone (parathormone). Affected individuals may also have other kinds of birth defect including kidney abnormalities and significant feeding difficulties as babies. Gastrointestinal issues are also very common in this patient population. Digestive motility issues may result in constipation. Disorders such as hypothyroidism and hypoparathyroidism or thrombocytopenia (low platelet levels), and psychiatric illnesses are common late-occurring features.
Microdeletions in chromosomal region 22q11.2 are associated with a 20 to 30-fold increased risk of schizophrenia. Studies provide various rates of DiGeorge syndrome in schizophrenia, ranging from 0.5 to 2.0% and averaging about 1.0%, compared with the overall estimated 0.025% risk of the 22q11.2 deletion syndrome in the general population.
Salient features can be summarized using the mnemonic CATCH-22 to describe 22q11.2 deletion syndrome, with the 22 to remind one the chromosomal abnormality is found on the 22 chromosome, as below:
Individuals with a 22q11.2 deletion can have many possible features, ranging in number of associated features and from the mild to the very serious. Symptoms shown to be common include:
- Congenital heart disease (40% of individuals), particularly conotruncal malformations (interrupted aortic arch (50%), persistent truncus arteriosus (34%), tetralogy of Fallot, and ventricular septal defect)
- Cyanosis (bluish skin due to poor circulation of oxygen-rich blood)
- Palatal abnormalities (50%), particularly velopharyngeal incompetence, submucosal cleft palate, and cleft palate; characteristic facial features (present in the majority of Caucasian individuals) including hypertelorism
- Learning difficulties (90%), including cognitive deficits, attention deficit disorders
- Hypocalcemia (50%)(due to hypoparathyroidism)
- Significant feeding problems (30%)
- Renal anomalies (37%)
- Hearing loss (both conductive and sensorineural) (hearing loss with craniofacial syndromes)
- Laryngotracheoesophageal anomalies
- Growth hormone deficiency
- Autoimmune disorders
- Immune disorders due to reduced T cell numbers
- Seizures (with or without hypocalcemia)
- Skeletal abnormalities
- Psychiatric disorders
This syndrome is characterized by incomplete penetrance and therefore there is a marked variability in clinical expression between the different patients. This often makes early diagnosis difficult.
Children with 22q11.2 have a specific profile in neuropsychological tests. They usually have a below-borderline normal IQ, with most individuals having higher scores in the verbal than the nonverbal domains. Some are able to attend normal schools, while others are home-schooled or in special classes. The severity of hypocalcemia early in childhood is associated with autism-like behavioral difficulties.
Individuals with 22q11.2DS also have a higher risk of developing early onset Parkinson's disease (PD). Diagnosis of PD in 22q11.2DS patients can be delayed by up to 10 years due to the use of antipsychotics, which can cause parkinsonian symptoms.
Speech and language
Current research demonstrates a unique profile of speech and language impairments is associated with 22q11.2 deletion syndrome. Children often perform lower on speech and language evaluations in comparison to their nonverbal IQ scores.[contradictory] Common problems include hypernasality, language delays, and speech sound errors.
Hypernasality occurs when air escapes through the nose during the production of oral speech sounds, resulting in reduced intelligibility. This is a common characteristic in the speech and language profile because 69% of children have palatal abnormalities. If the structure of the soft palate velum is such that it does not stop the flow of air from going up to the nasal cavity, it will cause hypernasal speech. This phenomenon is referred as velopharyngeal inadequacy (VPI). Hearing loss can also contribute to increased hypernasality because children with hearing impairments can have difficulty self monitoring their oral speech output. The treatment options available for VPI include prosthesis and surgery.
Difficulties acquiring vocabulary and formulating spoken language (expressive language deficits) at the onset of language development are also part of the speech and language profile associated with the 22q11.2 deletion. Vocabulary acquisition is often severely delayed for preschool-age children. In some recent studies, children had a severely limited vocabulary or were still not verbal at 2–3 years of age. School-age children do make progress with expressive language as they mature, but many continue to have delays and demonstrate difficulty when presented with language tasks such as verbally recalling narratives and producing longer and more complex sentences. Receptive language, which is the ability to comprehend, retain, or process spoken language, can also be impaired, although not usually with the same severity as expressive language impairments.
Articulation errors are commonly present in children with 22q11.2 deletion syndrome. These errors include a limited phonemic (speech sound) inventory and the use of compensatory articulation strategies resulting in reduced intelligibility. The phonemic inventory typically produced consists of sounds made in the front or back of the oral cavity such as: /p/, /w/, /m/, /n/, and glottal stops. Sound made in the middle of the mouth are completely absent. Compensatory articulation errors made by this population of children include: glottal stops, nasal substitutions, pharyngeal fricatives, linguapalatal sibilants, reduced pressure on consonant sounds, or a combination of these symptoms. Of these errors, glottal stops have the highest frequency of occurrence. It is reasoned that a limited phonemic inventory and the use of compensatory articulation strategies is present due to the structural abnormalities of the palate. The speech impairments exhibited by this population are more severe during the younger ages and show a trend of gradual improvement as the child matures.
22q11.2 deletion syndrome is caused by a heterozygous deletion of part of the long arm (q) of chromosome 22, region 1, band 1, sub-band 2 (22q11.2). Approximately 80-90% of patients have a deletion of 3Mb and 8% have a deletion of 1.5Mb. The number of genes affected by the deletion has been cited as approximately 30 to 50. Very rarely, patients with somewhat similar clinical features may have deletions on the short arm of chromosome 10. The disorder has an autosomal dominant inheritance pattern. A French study of 749 people diagnosed between 1995 and 2013 found that the mutation was inherited in 15% of patients, of which 85.5% was from the mother. Other studies have found inheritance rates of 6-10%. The majority cases are a result of a de novo (new to the family) deletion. This is because the 22q11 region has a structure that makes it highly prone to rearrangements during sperm or egg formation.
The exact mechanism that causes all of the associated features of the syndrome is unknown. Of the 30-50 genes in the deleted region, a number have been identified as possibly playing a role in the development of some of the signs and symptoms.
Haploinsufficiency of the TBX1 gene (T-box transcription factor TBX1) is thought to be the cause of some of the symptoms observed. Point mutations in this gene have also been observed in individuals with 22q11.2 deletion syndrome. TBX1 is part of the T-box family of genes which have an important role in tissue and organ formation during embryonic development and it may have a role in the regulation of differentiation of post migration neural crest cells. The neural crest forms many of the structures affected in 22q11.2 deletion syndrome, including the skull bones, mesenchyme of the face and palate, the outflow tract of the heart, and the thymus and parathyroid stroma. When there is a loss of expression of FGF18 during the development of the pharyngeal arches, neural crest cell death is seen. Although neither FGF18 or TBX1 are expressed in the neural crest cells, TBX1 might have a role in the regulation of FGF18 expression, ensuring that the differentiation of these cells in the pharyngeal region is correct. Therefore, dysfunction of TBX1 may be responsible for some of the symptoms in 22q11.2 deletion syndrome.
The abnormalities seen in the great arteries of mice deficient of Tbx1 are a consequence of abnormal formation and remodelling of the aortic arches during early development. The role of Tbx1 for correct formation and remodelling of the aortic arches has been extensively studied in various mouse models suggesting the key role of Tbx1 for cardiovascular development and the phenotypes seen in 22q11.2 deletion syndrome patients.
Parkinson's disease genes
22q11.2DS has been associated with a higher risk of early onset Parkinson's disease (PD). The neuropathology seen is similar to LRRK2-associated PD. None of the genes affected in individuals with 22q11.2DS have previously been linked to PD but there are a number that are likely candidates. These include DGCR8 which is important for biogenesis of brain mircoDNA, SRPT5 which encodes a protein that interacts with the PARK2 protein, COMT which is involved in regulating dopamine levels, and microRNA miR-185 which is thought to target known PD loci LRRK2.
Diagnosis of 22q11.2 deletion syndrome can be difficult due to the number of potential symptoms and the variation in phenotypes between individuals. It is suspected in patients with one or more signs of the deletion. In these cases a diagnosis of 22q11.2DS is confirmed by observation of a deletion of part of the long arm (q) of chromosome 22, region 1, band 1, sub-band 2. Genetic analysis is normally performed using fluorescence in situ hybridization (FISH), which is able to detect microdeletions that standard karyotyping (e.g. G-banding) miss. Newer methods of analysis include Multiplex ligation-dependent probe amplification assay (MLPA) and quantitative polymerase chain reaction (qPCR), both of which can detect atypical deletions in 22q11.2 that are not detected by FISH. qPCR analysis is also quicker than FISH, which can have a turn around of 3 to 14 days. A 2008 study of a new high-definition MLPA probe developed to detect copy number variation at 37 points on chromosome 22q found it to be as reliable as FISH in detecting normal 22q11.2 deletions. It was also able to detect smaller atypical deletions that are easily missed using FISH. These factors, along with the lower expense and easier testing mean that this MLPA probe could replace FISH in clinical testing.
Genetic testing using BACs-on-Beads has been successful in detecting deletions consistent with 22q11.2DS during prenatal testing. Array-comparative genomic hybridization (array-CGH) uses a large number of probes embossed in a chip to screen the entire genome for deletions or duplications. It can be used in post and pre-natal diagnosis of 22q11.2.
Fewer than 5% of individuals with clinical symptoms of the 22q11.2 deletion syndrome have normal routine cytogenetic studies and negative FISH testing. In these cases atypical deletions are the cause. Some cases of 22q11.2 deletion syndrome have defects in other chromosomes, notably a deletion in chromosome region 10p14.
No cure is known for 22q11.2 deletion syndrome. Certain individual features are treatable using standard treatments. The key is to identify each of the associated features and manage each using the best available treatments.
For example, in children, it is important that the immune problems are identified early, as special precautions are required regarding blood transfusion and immunization with live vaccines. Thymus transplantation can be used to address absence of the thymus in the rare, so-called "complete" 22q11.2 deletion syndrome. Bacterial infections are treated with antibiotics. Cardiac surgery is often required for congenital heart abnormalities. Hypoparathyroidism causing hypocalcaemia often requires lifelong vitamin D and calcium supplements. Specialty clinics that provide multi-system care allow for individuals with 22q11.2 deletion syndrome to be evaluated for all of their health needs and allow for careful monitoring of the patients. An example of this type of system is the 22q Deletion Clinic at SickKids Hospital in Toronto, Canada, which provides children with 22q11 deletion syndrome ongoing support, medical care and information from a team of health care workers.
22q11.2 deletion syndrome was estimated to affect between one in 2000 and one in 4000 live births. This estimate is based on major birth defects and may be an underestimate, because some individuals with the deletion have few symptoms and may not have been formally diagnosed. It is one of the most common causes of mental retardation due to a genetic deletion syndrome.
The prevalence of 22q11.2DS has been expected to rise because of multiple reasons: (1) Thanks to surgical and medical advances, an increasing number of people are surviving heart defects associated with the syndrome. These individuals are in turn having children. The chances of a 22q11.2DS patient having an affected child is 50% for each pregnancy; (2) Parents who have affected children, but who were unaware of their own genetic conditions, are now being diagnosed as genetic testing become available; (3) Molecular genetics techniques such as FISH (fluorescence in situ hybridization) have limitations and have not been able to detect all 22q11.2 deletions. Newer technologies have been able to detect these atypical deletions.
The signs and symptoms of 22q11.2 deletion syndrome are so varied that different groupings of its features were once regarded as separate conditions. These original classifications included velocardiofacial syndrome, Shprintzen syndrome, DiGeorge sequence/syndrome, Sedlackova syndrome, and conotruncal anomaly face syndrome. All are now understood to be presentations of a single syndrome.
ICD-10 2015 version mentions 22q11.2DS using two codes: D82.1 (Di George syndrome) and Q93.81 (Velo-cardio-facial syndrome). The ICD-11 Beta Draft discusses the syndrome under “LD50.P1 CATCH 22 phenotype". However, since this syndrome is caused by the deletion of a small piece of chromosome 22, it is recommended that the name "22q11.2 deletion syndrome (22q11.2DS)" be used.
- Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
- James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
- Shprintzen, RJ; Goldberg, RB; Lewin, ML; Sidoti, EJ; Berkman, MD; Argamaso, RV; Young, D (January 1978). "A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome.". The Cleft palate journal. 15 (1): 56–62. PMID 272242.
- Burn, J; Takao, A; Wilson, D; Cross, I; Momma, K; Wadey, R; Scambler, P; Goodship, J (October 1993). "Conotruncal anomaly face syndrome is associated with a deletion within chromosome 22q11.". Journal of Medical Genetics. 30 (10): 822–4. doi:10.1136/jmg.30.10.822. PMC . PMID 8230157.
- "22q11.2 deletion syndrome". Genetics Home Reference. Retrieved 26 August 2015.
- "22q11.2 deletion syndrome". Genetics Home Reference. July 2013. Retrieved 15 May 2017.
- "22q11.2 deletion syndrome | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 15 May 2017.
- Kobrynski LJ, Sullivan KE (October 2007). "Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes". Lancet. 370 (9596): 1443–52. doi:10.1016/S0140-6736(07)61601-8. PMID 17950858.
- DiGeorge, A (1968). "Congenital absence of the thymus and its immunologic consequences: concurrence with congenital hypoparathyroidism.". March of Dimes-Birth Defects Foundation: 116–21.
- Restivo, Angelo; Sarkozy, Anna; Digilio, Maria Cristina; Dallapiccola, Bruno; Marino, Bruno (February 2006). "22q11 Deletion syndrome: a review of some developmental biology aspects of the cardiovascular system.". Journal of Cardiovascular Medicine. 7 (2): 77–85. doi:10.2459/01.JCM.0000203848.90267.3e. PMID 16645366.
- McDonald-McGinn, Donna; Sullivan, Kathleen (January 2011). "Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)". Medicine. 90: 1–18. doi:10.1097/MD.0b013e3182060469. PMID 21200182.
- Debbané M, Glaser B, David MK, Feinstein C, Eliez S (2006). "Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications". Schizophr. Res. 84 (2–3): 187–93. doi:10.1016/j.schres.2006.01.019. PMID 16545541.
- [non-primary source needed] Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R (2003). "The schizophrenia phenotype in 22q11 deletion syndrome". Am J Psychiatry. 160 (9): 1580–6. doi:10.1176/appi.ajp.160.9.1580. PMC . PMID 12944331.
- [non-primary source needed] Horowitz A, Shifman S, Rivlin N, Pisanté A, Darvasi A (2005). "A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients". Schizophr. Res. 73 (2–3): 263–7. doi:10.1016/j.schres.2004.02.008. PMID 15653270.
- Burn J (October 1999). "Closing time for CATCH22". J. Med. Genet. 36 (10): 737–8. doi:10.1136/jmg.36.10.737. PMC . PMID 10528851.
- Lindsay, EA (November 2001). "Chromosomal microdeletions: dissecting del22q11 syndrome.". Nature Reviews Genetics. 2 (11): 858–68. doi:10.1038/35098574. PMID 11715041.
- Swillen, A; Vogels, A; Devriendt, K; Fryns, JP (1999). "Chromosome 22q11 deletion syndrome: update and review of the clinical features, cognitive-behavioral spectrum, and psychiatric complications.". American Journal of Medical Genetics. 97 (2): 128–35. doi:10.1002/1096-8628(200022)97:2<128::AID-AJMG4>3.0.CO;2-Z. PMID 11180220.
- Muldoon et al. (2014) doi:10.1007/s00406-014-0546-0 PMID 25267002
- Zinkstok J, van Amelsvoort T (2005). "Neuropsychological profile and neuroimaging in patients with 22Q11.2 Deletion Syndrome: a review". Child Neuropsychol. 11 (1): 21–37. doi:10.1080/09297040590911194. PMID 15823981.
- Butcher NJ, Kiehl TR, Hazrati LN, Chow EW, Rogaeva E, Lang AE, Bassett AS (2013). "Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.". JAMA Neurol. 70: 1359–66. doi:10.1001/jamaneurol.2013.3646. PMC . PMID 24018986.
- D'Antonio LL, Scherer NJ, Miller LL, Kalbfleisch JH, Bartley JA (2001). "Analysis of speech characteristics in children with velocardiofacial syndrome (VCFS) and children with phenotypic overlap without VCFS". Cleft Palate Craniofac. J. 38 (5): 455–67. doi:10.1597/1545-1569(2001)038<0455:AOSCIC>2.0.CO;2. ISSN 1545-1569. PMID 11522167.
- Scherer NJ, D'Antonio LL, Kalbfleisch JH (1999). "Early speech and language development in children with velocardiofacial syndrome". Am. J. Med. Genet. 88 (6): 714–23. doi:10.1002/(SICI)1096-8628(19991215)88:6<714::AID-AJMG24>3.0.CO;2-B. PMID 10581495.
- Scherer NJ, D'Antonio LL, Rodgers JR (2001). "Profiles of communication disorder in children with velocardiofacial syndrome: comparison to children with Down syndrome". Genet. Med. 3 (1): 72–8. doi:10.1097/00125817-200101000-00016. PMID 11339384.
- Eliez S, Palacio-Espasa F, Spira A (2000). "Young children with Velo-Cardio-Facial syndrome (CATCH-22). Psychological and language phenotypes". Eur Child Adolesc Psychiatry. 9 (2): 109–14. doi:10.1007/s007870050005. PMID 10926060.
- Robin NH, Shprintzen RJ (2005). "Defining the clinical spectrum of deletion 22q11.2". J. Pediatr. 147 (1): 90–6. doi:10.1016/j.jpeds.2005.03.007. PMID 16027702.
- Solot CB, Knightly C, Handler SD (2000). "Communication disorders in the 22Q11.2 microdeletion syndrome". J Commun Disord. 33 (3): 187–203; quiz 203–4. doi:10.1016/S0021-9924(00)00018-6. PMID 10907715.
- Persson C, Niklasson L, Oskarsdóttir S, Johansson S, Jönsson R, Söderpalm E (2006). "Language skills in 5-8-year-old children with 22q11 deletion syndrome". Int J Lang Commun Disord. 41 (3): 313–33. doi:10.1080/13682820500361497. PMID 16702096.
- Online Mendelian Inheritance in Man (OMIM) #188400
- Packham, EA; Brook, JD (1 April 2003). "T-box genes in human disorders". Hum Mol Genet. 12 (Suppl 1): R37–44. doi:10.1093/hmg/ddg077. PMID 12668595. Retrieved 11 November 2015.
- Tang, KL; Antshel, KM; Fremont, WP; Kates, WR (October 2015). "Behavioral and Psychiatric Phenotypes in 22q11.2 Deletion Syndrome". J Dev Behav Pediatr. 36 (8): 639–50. doi:10.1097/DBP.0000000000000210. PMC . PMID 26372046.
- Maynard, TM; Meechan, DW; Dudevoir, ML; Gopalakrishna, D; Peters, AZ (November 2008). "Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes". Mol Cell Neurosci. 39 (3): 439–51. doi:10.1016/j.mcn.2008.07.027. PMC . PMID 18775783.
- Bartsch O, Nemecková M, Kocárek E, Wagner A, Puchmajerová A, Poppe M, Ounap K, Goetz P (2003). "DiGeorge/velocardiofacial syndrome: FISH studies of chromosomes 22q11 and 10p14, and clinical reports on the proximal 22q11 deletion". Am J Med Genet A. 117A (1): 1–5. doi:10.1002/ajmg.a.10914. PMID 12548732.
- Poirsier, C; Besseau-Ayasse, J (28 October 2015). "A French multicenter study of over 700 patients with 22q11 deletions diagnosed using FISH or aCGH". Eur J Hum Genet. 24: 844–51. doi:10.1038/ejhg.2015.219. PMC . PMID 26508576.
- McDonald-McGinn, Donna (2011). "Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).". Medicine (Baltimore). 90 (1): 1–18. doi:10.1097/MD.0b013e3182060469. PMID 21200182.
- Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE (1999). "A common molecular basis for rearrangement disorders on chromosome 22q11.". Hum Mol Genet. 8 (7): 1157–67. doi:10.1093/hmg/8.7.1157. PMID 10369860.
- Jerome, Loydie A.; Papaioannou, Virginia E. (2001). "Nature Citation". Nature Genetics. 27 (3): 286–291. doi:10.1038/85845. PMID 11242110.
- Lindsay, Elizabeth A.; Vitelli, Francesca; Su, Hong; Morishima, Masae; Huynh, Tuong; Pramparo, Tiziano; Jurecic, Vesna; Ogunrinu, George; Sutherland, Helen F. (2001). "http://www.nature.com/doifinder/10.1038/35065105". Nature. 410 (6824): 97–101. doi:10.1038/35065105. PMID 11242049. External link in
- Chun, Sungkun (28 November 2016). "Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion". Nature Medicine. doi:10.1038/nm.4240. Retrieved 5 December 2016.
- Tonelli AR, Kosuri K, Wei S, Chick D (2007). "Seizures as the first manifestation of chromosome 22q11.2 deletion syndrome in a 40-year old man: a case report". J Med Case Reports. 1: 167. doi:10.1186/1752-1947-1-167. PMC . PMID 18053182.
- Miller, Kimberley A. (2008). "FISH Diagnosis of 22q11.2 Deletion Syndrome". Newborn and Infant Nursing Reviews. 8 (1): e11–e19. doi:10.1053/j.nainr.2007.12.006.
- G.R. Jalali; J.A.S. Vorstman; Ab Errami; R. Vijzelaar; J. Biegel; T. Shaikh; B.S. Emanue (2008). "Detailed analysis of 22q11.2 with a high density MLPA probe set". Human Mutation. 29 (3): 433–440. doi:10.1002/humu.20640. PMC . PMID 18033723.
- García-Herrero,Sandra et. al. (2014). "BACs-on-Beads Technology: A Reliable Test for Rapid Detection of Aneuploidies and Microdeletions in Prenatal Diagnosis". BioMed Research International. 2014: 590298. doi:10.1155/2014/590298. PMC . PMID 24795887.
- Choy KW et. al. (2014). "Diagnostic accuracy of the BACs-on-Beads™ assay versus karyotyping for prenatal detection of chromosomal abnormalities: a retrospective consecutive case series.". BJOG. 121 (10): 1245–52. doi:10.1111/1471-0528.12873. PMID 24893808.
- Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, Cheon CK, Hwang SH, Kang HY (2011). "Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases.". Mol Cytogenet. 4: 12. doi:10.1186/1755-8166-4-12. PMC . PMID 21549014.
- Mupanemunda, Richard H.; Watkinson, Michael (2004). Key Topics in Neonatology. CRC Press. p. 82. ISBN 9781859962343.
- Markert ML, Devlin BH, Alexieff MJ (2007). "Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants". Blood. 109 (10): 4539–47. doi:10.1182/blood-2006-10-048652. PMC . PMID 17284531.
- "Clinical and Metabolic Genetics- The 22q Deletion Clinic". The Hospital for Sick Children.
- Oskarsdóttir S, Vujic M, Fasth A (2004). "Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden". Arch. Dis. Child. 89 (2): 148–51. doi:10.1136/adc.2003.026880. PMC . PMID 14736631.
- Daily DK, Ardinger HH, Holmes GE (February 2000). "Identification and evaluation of mental retardation". Am Fam Physician. 61 (4): 1059–67, 1070. PMID 10706158.
- "The Genetics of 22q11.2 DS: Demographics". Information for Medical Professionals. The Dalglish Family Hearts and Minds Clinic for Adults with 22q11.2 Deletion Syndrome. Retrieved 26 August 2015.
- Fung, Wai Lun Alan (2015). "Practical guidelines for managing adults with 22q11.2 deletion syndrome". Genetics in Medicine. 17 (8): 599–609. doi:10.1038/gim.2014.175. PMC . PMID 25569435.
- Grati, Francesca (2015). "Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies". Prenatal Diagnosis. 35 (8): 801–809. doi:10.1002/pd.4613. PMID 25962607.
- "Di George's syndrome". 2015 ICD-10-CM Diagnosis Code D82.1. Retrieved 26 August 2015.
- "Velo-cardio-facial syndrome". 2015 ICD-10-CM Diagnosis Code Q93.81. Retrieved 26 August 2015.
- Bassett, Anne (August 2011). "Practical Guidelines for Managing Patients with 22q11.2 Deletion Syndrome". J Pediatr. 159 (2): 332–39. doi:10.1016/j.jpeds.2011.02.039. PMC . PMID 21570089.
- McDonald-McGinn, Donna (2011). "Chromosome 22q11.2 Deletion Syndrome (DiGeorge syndrome/velocardiofacial syndrome)". Medicine (Baltimore). 90 (1): 1–18. doi:10.1097/MD.0b013e3182060469. PMID 21200182.
This article incorporates public domain text from The U.S. National Library of Medicine
Media related to DiGeorge Syndrome at Wikimedia Commons
- DiGeorge syndrome at DMOZ
- McDonald-McGinn DM, Emanuel BS, Zackai EH (December 16, 2005). "22q11.2 Deletion Syndrome". In Pagon RA, Bird TD, Dolan CR, Stephens K. GeneReviews. PMID 20301696. NBK1523.
- Firth HV (February 17, 2009). "22q11.2 Duplication". In Pagon RA, Bird TD, Dolan CR, Stephens K. GeneReviews. PMID 20301749. NBK3823.